BACKGROUND: Vascular endothelial growth factor (VEGF) is a candidate susceptibility gene to inflammatory bowel disease (IBD), both from a functional as well as genetic perspective. Moreover, serum VEGF (sVEGF) levels are increased in IBD and correlate with disease activity. Both VEGF expression and sVEGF levels may be influenced by VEGF gene polymorphisms. AIMS: To study VEGF polymorphisms in IBD susceptibility and their impact on sVEGF levels. METHODS: Four functional VEGF polymorphisms (-C2578A, -G1154A, -G634C, and C936T) were genotyped in two independent cohorts (cohort 1: 372 IBD trios; cohort 2: 452 unrelated IBD patients, 271 healthy controls [HC]; and 93 patients with non-IBD gastrointestinal inflammation [non-IBD GI]), using polymerase chain reaction with restriction fragment length polymorphism and TaqMan minor groove binding. Phenotypical data on all patients as well as sVEGF levels were correlated with the genetic data. RESULTS: Both the VEGF genotype and haplotype frequencies did not differ between IBD patients and controls, and no distortion of transmission was observed. sVEGF levels were increased in IBD but also in non-IBD GI patients, compared with HC, and were only influenced by VEGF polymorphisms in patients with Crohn's disease (-G1154A genotype and -2578/-1154/-634 AAG promoter haplotype). CONCLUSIONS: The VEGF polymorphisms studied are not implicated in susceptibility to IBD and do not predict sVEGF levels. Although increased sVEGF and angiogenesis are important features of IBD, they do not appear genetically determined.
BACKGROUND:Vascular endothelial growth factor (VEGF) is a candidate susceptibility gene to inflammatory bowel disease (IBD), both from a functional as well as genetic perspective. Moreover, serum VEGF (sVEGF) levels are increased in IBD and correlate with disease activity. Both VEGF expression and sVEGF levels may be influenced by VEGF gene polymorphisms. AIMS: To study VEGF polymorphisms in IBD susceptibility and their impact on sVEGF levels. METHODS: Four functional VEGF polymorphisms (-C2578A, -G1154A, -G634C, and C936T) were genotyped in two independent cohorts (cohort 1: 372 IBD trios; cohort 2: 452 unrelated IBD patients, 271 healthy controls [HC]; and 93 patients with non-IBD gastrointestinal inflammation [non-IBD GI]), using polymerase chain reaction with restriction fragment length polymorphism and TaqMan minor groove binding. Phenotypical data on all patients as well as sVEGF levels were correlated with the genetic data. RESULTS: Both the VEGF genotype and haplotype frequencies did not differ between IBD patients and controls, and no distortion of transmission was observed. sVEGF levels were increased in IBD but also in non-IBD GIpatients, compared with HC, and were only influenced by VEGF polymorphisms in patients with Crohn's disease (-G1154A genotype and -2578/-1154/-634 AAG promoter haplotype). CONCLUSIONS: The VEGF polymorphisms studied are not implicated in susceptibility to IBD and do not predict sVEGF levels. Although increased sVEGF and angiogenesis are important features of IBD, they do not appear genetically determined.
Authors: Sara Remuzgo-Martínez; Fernanda Genre; Verónica Pulito-Cueto; Belén Atienza-Mateo; Víctor Manuel Mora Cuesta; David Iturbe Fernández; Sonia María Fernández Rozas; Leticia Lera-Gómez; Pilar Alonso Lecue; María Piedad Ussetti; Rosalía Laporta; Cristina Berastegui; Amparo Solé; Virginia Pérez; Alicia De Pablo Gafas; Oreste Gualillo; José Manuel Cifrián; Raquel López-Mejías; Miguel Ángel González-Gay Journal: Biomedicines Date: 2021-04-22
Authors: Seung Hoan Choi; Daniela Ruggiero; Rossella Sorice; Ci Song; Teresa Nutile; Albert Vernon Smith; Maria Pina Concas; Michela Traglia; Caterina Barbieri; Ndeye Coumba Ndiaye; Maria G Stathopoulou; Vasiliki Lagou; Giovanni Battista Maestrale; Cinzia Sala; Stephanie Debette; Peter Kovacs; Lars Lind; John Lamont; Peter Fitzgerald; Anke Tönjes; Vilmundur Gudnason; Daniela Toniolo; Mario Pirastu; Celine Bellenguez; Ramachandran S Vasan; Erik Ingelsson; Anne-Louise Leutenegger; Andrew D Johnson; Anita L DeStefano; Sophie Visvikis-Siest; Sudha Seshadri; Marina Ciullo Journal: PLoS Genet Date: 2016-02-24 Impact factor: 5.917
Authors: M Scartozzi; M Bianconi; L Faloppi; C Loretelli; A Bittoni; M Del Prete; R Giampieri; E Maccaroni; S Nicoletti; L Burattini; D Minardi; G Muzzonigro; R Montironi; S Cascinu Journal: Br J Cancer Date: 2012-11-29 Impact factor: 7.640
Authors: Giovanni Sarnelli; Alessandra D'Alessandro; Teresa Iuvone; Elena Capoccia; Stefano Gigli; Marcella Pesce; Luisa Seguella; Nicola Nobile; Giovanni Aprea; Francesco Maione; Giovanni Domenico de Palma; Rosario Cuomo; Luca Steardo; Giuseppe Esposito Journal: PLoS One Date: 2016-05-24 Impact factor: 3.240